Basal Insulin-Fc (BIF) is currently in clinical development for type 2 diabetes mellitus (T2DM). T2DM is a lifelong condition that develops when the body becomes resistant to or does not produce enough insulin – a hormone produced in the pancreas that enables sugar to enter body cells. Signs and symptoms of T2DM often develop slowly. When signs and symptoms are present, they may include increased thirst, frequent urination, increased hunger, unintended weight loss etc. Current treatment options require daily insulin injections which can hinder adherence to treatment and be a burden to individuals.
Basal Insulin-Fc for type 2 diabetes mellitus
Basal Insulin-Fc (BIF) is currently in clinical development for type 2 diabetes mellitus (T2DM). T2DM is a lifelong condition that develops when the body becomes resistant to or does not produce enough insulin – a hormone produced in the pancreas that enables sugar to enter body cells.
Interventions:
Basal Insulin-Fc
Indications:
Type 2 diabetes
Therapeutic Areas:
Endocrine Nutritional and Metabolic Disorders
Year:
2023